Takeda Pharmaceuticals has backed a round that will help Prosetta continue research and development into treatments for a range of central nervous system disorders.
US-based biotechnology company Prosetta Biosciences secured $31m in series D capital on Thursday through a private placement from a consortium of investors including drug developer Takeda Pharmaceuticals.
Investment firm Alger Management led the round, which also featured several unnamed backers.
Founded in 2002, Prosetta is working to create treatments for conditions affecting the central nervous system, including cancer and inflammation, as well as products aimed at animal health and biodefence.
Prosetta will use the proceeds to support research and development…
